Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi

@article{Trachtenberg2011RationaleAD,
  title={Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and effi},
  author={Barry H. Trachtenberg and Darcy L. DiFede Velazquez and Adam Williams and I K Mcniece and Joel E. Fishman and Kim Chung Nguyen and Didier Rouy and Peter A Altman and Richard H. Schwarz and Adam M. Mendizabal and Behzad N. Oskouei and J. B. Byrnes and V{\'i}ctor Soto and Melissa Tracy and Juan Pablo Zambrano and Alan W. Heldman and Joshua M Hare},
  journal={American heart journal},
  year={2011},
  volume={161 3},
  pages={487-93}
}
Although there is tremendous interest in stem cell (SC)-based therapies for cardiomyopathy caused by chronic myocardial infarction, many unanswered questions regarding the best approach remain. The TAC-HFT study is a phase I/II randomized, double-blind, placebo-controlled trial designed to address several of these questions, including the optimal cell type, delivery technique, and population. This trial compares autologous mesenchymal SCs (MSCs) and whole bone marrow mononuclear cells (BMCs… CONTINUE READING
67 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…